Holen Sie sich die Stockscreener-App
4.71
3.52%
0.16
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus
DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus
Precision Biosciences Q1 Income From Operations USD -22.112 Million - marketscreener.com
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Accelerates PBGENE-DMD Program for DMD - TipRanks
Precision BioSciences Accelerates Development of PBGENE-DMD With - GuruFocus
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - BioSpace
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 | DTIL Stock News - GuruFocus
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - GuruFocus
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | DTIL Stock News - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 29, 2025 - BioSpace
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Precision BioSciences Strengthens Gene Editing Team with Strategic RSU Awards to New Hires - Stock Titan
Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace
Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia
Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus
Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com
Precision BioSciences, Inc. Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - marketscreener.com
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - 01net
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):